Bertis is a proteomics company who envisions to unravel the proteome for the next era of precision medicine. Since our establishment in 2014, we have achieved significant milestones such as regulatory clearances in Korea and geographical expansion to SEA & MENA. Bertis' first product MASTOCHECK, breast cancer early detection test based on the proteomics biomarkers, received efficacy and safety approval from the MFDS, known as Korean FDA in 2019. Since then, we were able to obtain service agreement contracts with over 480 different major institutions in Korea, marking a significant achievement for an innovative product launched for the first time. MASTOCHECK’s use cases have been exponentially increasing since 2020. It has reached accumulated cases of 170,000 at the end of 2023. Bertis is gradually expanding its presence globally. Thus far, Bertis has entered into service agreements with major medical groups in Singapore, as well as in Saudi Arabia.